Anti-prion Protein Antibody 6D11 Restores Cellular Proteostasis of Prion Protein Through Disrupting Recycling Propagation of PrPSc and Targeting PrPSc for Lysosomal Degradation
- 117 Downloads
PrPSc is an infectious and disease-specific conformer of the prion protein, which accumulation in the CNS underlies the pathology of prion diseases. PrPSc replicates by binding to the cellular conformer of the prion protein (PrPC) expressed by host cells and rendering its secondary structure a likeness of itself. PrPC is a plasma membrane anchored protein, which constitutively recirculates between the cell surface and the endocytic compartment. Since PrPSc engages PrPC along this trafficking pathway, its replication process is often referred to as “recycling propagation.” Certain monoclonal antibodies (mAbs) directed against prion protein can abrogate the presence of PrPSc from prion-infected cells. However, the precise mechanism(s) underlying their therapeutic propensities remains obscure. Using N2A murine neuroblastoma cell line stably infected with 22L mouse-adapted scrapie strain (N2A/22L), we investigated here the modus operandi of the 6D11 clone, which was raised against the PrPSc conformer and has been shown to permanently clear prion-infected cells from PrPSc presence. We determined that 6D11 mAb engages and sequesters PrPC and PrPSc at the cell surface. PrPC/6D11 and PrPSc/6D11 complexes are then endocytosed from the plasma membrane and are directed to lysosomes, therefore precluding recirculation of nascent PrPSc back to the cell surface. Targeting PrPSc by 6D11 mAb to the lysosomal compartment facilitates its proteolysis and eventually shifts the balance between PrPSc formation and degradation. Ongoing translation of PrPC allows maintaining the steady-state level of prion protein within the cells, which was not depleted under 6D11 mAb treatment. Our findings demonstrate that through disrupting recycling propagation of PrPSc and promoting its degradation, 6D11 mAb restores cellular proteostasis of prion protein.
KeywordsEndo-lysosomal system Proteostasis Monoclonal antibody Passive immunization Prion protein PrPSc conformer Recycling propagation
This work was supported by the following awards from the National Institute on Aging R01 AG029635 (MJS), R01 AG031221 (MJS), and R01 AG053990 (MJS), and by the following award from the National Science Foundation CHE-1507946 (KK).
Compliance with Ethical Standards
All mouse care and experimental procedures were approved by the Institutional Animal Care and Use Committee of the New York University School of Medicine.
Conflict of Interest
JEP, SS, KK, and MJS declare no competing interests. RBK and RJK receive royalties for licensing the 6D11 clones, which currently is marketed by BioLegend (San Diego, CA).
- 1.Sadowski M, Kumar A, Wisniewski T (2008) Prion diseases. In: Bradley WG (ed) Neurology in clinical practice,. 5th edition edn. Butterworth-Heinemann, pp. 1567–1581Google Scholar
- 3.Geschwind MD (2015) Prion diseases. Continuum (MinneapMinn):1612-1638. doi: https://doi.org/10.1212/CON.0000000000000251 00132979-201512000-00011
- 12.Jeffrey M, McGovern G, Siso S, Gonzalez L (2011) Cellular and sub-cellular pathology of animal prion diseases: relationship between morphological changes, accumulation of abnormal prion protein and clinical disease. Acta Neuropathol 121(1):113–134. https://doi.org/10.1007/s00401-010-0700-3 CrossRefPubMedGoogle Scholar
- 13.Goold R, McKinnon C, Tabrizi SJ (2015) Prion degradation pathways: potential for therapeutic intervention. Mol Cell Neurosci 66, 12:–20. https://doi.org/10.1016/j.mcn.2014.12.009
- 16.Mallucci GR, White MD, Farmer M, Dickinson A, Khatun H, Powell AD, Brandner S, Jefferys JG et al (2007) Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice. Neuron 53(3):325–335. https://doi.org/10.1016/j.neuron.2007.01.005 CrossRefPubMedGoogle Scholar
- 20.Xiao Q, Yan P, Ma X, Liu H, Perez R, Zhu A, Gonzales E, Burchett JM et al (2014) Enhancing astrocytic lysosome biogenesis facilitates Abeta clearance and attenuates amyloid plaque pathogenesis. J Neurosci 34(29):9607–9620. https://doi.org/10.1523/JNEUROSCI.3788-13.2014 CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Sadowski MJ, Pankiewicz J, Prelli F, Scholtzova H, Spinner DS, Kascsak RB, Kascsak RJ, Wisniewski T (2009) Anti-PrP Mab 6D11 suppresses PrPSc replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo. Neurobiol Dis 34(2):267–278CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Spinner DR, Kascsak RB, LaFauci G, Meeker HC, Ye X, Flory MJ, Kim JI, Schuller-Lewis GB et al (2007) CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils. J Leukoc Biol 81(6):1374–1385CrossRefPubMedGoogle Scholar
- 26.Jimenez-Huete A, Alfonso P, Soto C, Albar JP, Rabano A, Ghiso J, Frangione B (1998) Antibodies directed to the carboxyl terminus of amyloid beta-peptide recognize sequence epitopes and distinct immunoreactive deposits in Alzheimer’s disease brain. Alzheimers Reports 1(1):41–47Google Scholar
- 29.Burgess A, Vigneron S, Brioudes E, Labbe JC, Lorca T, Castro A (2010) Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance. Proc Natl Acad Sci U S A 107(28):12564–12569. https://doi.org/10.1073/pnas.0914191107 CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Liberski PP, Sikorska B, Hauw JJ, Kopp N, Streichenberger N, Giraud P, Boellaard J, Budka H et al (2010) Ultrastructural characteristics (or evaluation) of Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies or prion diseases. Ultrastruct Pathol 34(6):351–361. https://doi.org/10.3109/01913123.2010.491175 CrossRefPubMedGoogle Scholar
- 45.Novak P, Schmidt R, Kontsekova E, Zilka N, Kovacech B, Skrabana R, Vince-Kazmerova Z, Katina S et al (2017) Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet Neurol 16(2):123–134. https://doi.org/10.1016/S1474-4422(16)30331-3 CrossRefPubMedGoogle Scholar
- 46.West T, Hu Y, Verghese PB, Bateman RJ, Braunstein JB, Fogelman I, Budur K, Florian H et al (2017) Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer’s disease and other tauopathies. J Prev Alz Dis 4(4):236–241. https://doi.org/10.14283/jpad.2017.36 Google Scholar
- 57.Gill ON, Spencer Y, Richard-Loendt A, Kelly C, Dabaghian R, Boyes L, Linehan J, Simmons M et al (2013) Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ 347:f5675. https://doi.org/10.1136/bmj.f5675 CrossRefPubMedPubMedCentralGoogle Scholar
- 59.Luginbuhl B, Kanyo Z, Jones RM, Fletterick RJ, Prusiner SB, Cohen FE, Williamson RA, Burton DR et al (2006) Directed evolution of an anti-prion protein scFv fragment to an affinity of 1 pM and its structural interpretation. J Mol Biol 363(1):75–97. https://doi.org/10.1016/j.jmb.2006.07.027 CrossRefPubMedGoogle Scholar
- 60.Padiolleau-Lefevre S, Alexandrenne C, Dkhissi F, Clement G, Essono S, Blache C, Couraud JY, Wijkhuisen A et al (2007) Expression and detection strategies for an scFv fragment retaining the same high affinity than Fab and whole antibody: implications for therapeutic use in prion diseases. Mol Immunol 44(8):1888–1896. https://doi.org/10.1016/j.molimm.2006.09.035 CrossRefPubMedGoogle Scholar